Goldman Sachs Upgrades AbbVie to Buy, Announces $173 Price Target
Portfolio Pulse from Benzinga Newsdesk
Goldman Sachs analyst Chris Shibutani has upgraded AbbVie (NYSE:ABBV) from Neutral to Buy and set a price target of $173.
December 11, 2023 | 1:13 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
AbbVie has been upgraded by Goldman Sachs from Neutral to Buy with a new price target of $173, indicating a positive outlook on the stock.
Analyst upgrades typically lead to a positive short-term reaction in the stock market as they suggest a better-than-expected future performance. The new price target of $173 by Goldman Sachs is likely to instill confidence among investors, potentially driving up the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100